Shares of UnitedHealth Group Inc (NYSE:UNH) ended Friday session in green amid volatile trading. The shares closed up +0.87 points or 0.64% at $136.61 with 2.39 million shares getting traded. Post opening the session at $136.50, the shares hit an intraday low of $135.76 and an intraday high of $136.78 and the price vacillated in this range throughout the day. The company has a market cap of $129.81 billion and the numbers of outstanding shares have been calculated to be 952.39 million shares.
On September 1, 2016 UnitedHealthcare and Optum, the health benefits and services companies of UnitedHealth Group (UNH), are taking immediate action to help people affected by Hurricane Madeline and Hurricane Lester, which are expected to hit Hawaii over the next few days.
This includes a free emotional-support line to help people in the affected communities, and assisting health plan participants who may be affected and need to make alternate arrangements to ensure continuity of care.
Free Help Line: Optum, a leading health and behavioral health services company, is offering a free emotional-support help line.
The toll-free number, 866-342-6892, will be open 24 hours a day, seven days a week, for as long as necessary. The service is free of charge and open to anyone. Specially trained Optum mental health specialists help people manage their stress and anxiety so they can continue to address their everyday needs. Callers may also receive referrals to community resources to help them with specific concerns, including financial and legal matters.
Along with the toll-free help line, emotional-support resources and information are available online at www.liveandworkwell.com.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) ended Friday session in red amid volatile trading. The shares closed down -0.78 points or -4.19% at $17.84 with 4.36 million shares getting traded. Post opening the session at $18.71, the shares hit an intraday low of $17.68 and an intraday high of $18.96 and the price vacillated in this range throughout the day. The company has a market cap of $3.00 billion and the numbers of outstanding shares have been calculated to be 160.90 million shares.
Horizon Pharma PLC (HZNP) on Aug. 08, 2016 announced its second-quarter 2016 financial results and confirmed its full-year 2016 net sales and adjusted EBITDA guidance.
“We exceeded our expectations for the second quarter with another quarter of record net sales and remain on track to meet our objectives for the full year,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “We continued to execute across all levels of the organization, generating new patient and prescription growth and advancing our pipeline of orphan medicines, including the completion of enrollment in our Phase 3 clinical trial for ACTIMMUNE in Friedreich’s ataxia and the submission of our supplemental new drug application for RAVICTI.”
Second-Quarter 2016 Financial Results.
- Gross Profit: Under U.S. generally accepted accounting principles (GAAP) in the second quarter of 2016, the gross profit ratio was 68.5 percent compared to 64.2 percent in the second quarter of 2015. The non-GAAP gross profit ratio in the second quarter of 2016 was 92.0 percent compared to 91.1 percent in the second quarter of 2015.
- Operating Expenses: On a GAAP basis in the second quarter of 2016, total operating expenses were 56.3 percent of sales. Research & development (R&D) expenses were 4.4 percent of sales, sales & marketing (S&M) expenses were 30.9 percent of sales and general & administrative (G&A) expenses were 21.0 percent of sales. Non-GAAP total operating expenses in the second quarter of 2016 were 44.9 percent of sales. Non-GAAP R&D expenses were 3.3 percent of sales, non-GAAP S&M expenses were 28.1 percent of sales and non-GAAP G&A expenses were 13.5 percent of sales.